Roux-en-Y gastric bypass surgery changes fungal and bacterial microbiota in morbidly obese patients-A pilot study.
Adult
Bacteria
/ classification
DNA, Intergenic
Feces
/ microbiology
Female
Fungi
/ classification
Gastric Bypass
Gastrointestinal Microbiome
/ genetics
Genes, Bacterial
Genes, Fungal
Humans
Male
Metagenomics
Microbiota
Middle Aged
Mycobiome
Obesity, Morbid
/ microbiology
Pilot Projects
RNA, Ribosomal, 16S
/ genetics
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
01
2020
accepted:
16
07
2020
entrez:
1
8
2020
pubmed:
1
8
2020
medline:
30
9
2020
Statut:
epublish
Résumé
The Roux-en-Y gastric bypass (RYGB) remains the most effective treatment for morbidly obese patients to lower body weight and improve glycemic control. There is recent evidence that the mycobiome (fungal microbiome) can aggravate disease severity in a number of diseases including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and hepatitis; moreover, a dysbiotic fungal microbiota has been reported in the obese. We characterized fungal and bacterial microbial composition in fecal samples of 16 morbidly obese patients before and three months after RYGB surgery and compared with nine healthy controls. We found that RYGB surgery induced a clear alteration in structure and composition of the gut fungal and bacterial microbiota. Beta diversity analysis revealed significant differences in bacterial microbiota between obese patients before surgery and healthy controls (P < 0.005) and a significant, unidirectional shift in RYGB patients after surgery (P < 0.001 vs. before surgery). In contrast, there was no significant difference in fungal microbiota between groups but individually specific changes after RYGB surgery. Interestingly, RYGB surgery induced a significant reduction in fungal alpha diversity namely Chao1, Sobs, and Shannon diversity index (P<0.05, respectively) which contrasts the trend for uniform changes in bacteria towards increased richness and diversity post-surgery. We did not observe any inter-kingdom relations in RYGB patients but in the healthy control cohort and there were several correlations between fungi and bacteria and clinical parameters (P<0.05, respectively) that warrant further research. Our study identifies changes in intestinal fungal communities in RYGB patients that are distinct to changes in the bacterial microbiota.
Identifiants
pubmed: 32735609
doi: 10.1371/journal.pone.0236936
pii: PONE-D-20-02342
pmc: PMC7394366
doi:
Substances chimiques
DNA, Intergenic
0
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0236936Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Appl Environ Microbiol. 2009 Dec;75(23):7537-41
pubmed: 19801464
Nat Rev Gastroenterol Hepatol. 2018 Oct;15(10):606-624
pubmed: 30181611
Gut. 2019 Jan;68(1):70-82
pubmed: 29899081
Diabetes. 2007 Jul;56(7):1761-72
pubmed: 17456850
PLoS One. 2013;8(3):e59474
pubmed: 23555039
Am J Surg. 1976 Feb;131(2):162-8
pubmed: 1251957
Obes Surg. 2012 May;22(5):740-8
pubmed: 22354457
Gut. 2017 Jun;66(6):1039-1048
pubmed: 26843508
Gut Pathog. 2014 Oct 15;6(1):43
pubmed: 25328543
Diagn Microbiol Infect Dis. 2011 Aug;70(4):492-8
pubmed: 20846815
Diabetes. 2010 Dec;59(12):3049-57
pubmed: 20876719
Obes Surg. 2017 May;27(5):1345-1357
pubmed: 28265960
Front Microbiol. 2017 Jul 31;8:1432
pubmed: 28824566
Cell. 2012 Mar 16;148(6):1258-70
pubmed: 22424233
Nat Rev Gastroenterol Hepatol. 2012 Feb 21;9(4):219-30
pubmed: 22349170
Appl Environ Microbiol. 2007 Aug;73(16):5261-7
pubmed: 17586664
Nature. 2014 Jan 23;505(7484):559-63
pubmed: 24336217
Am J Clin Nutr. 2013 Jul;98(1):16-24
pubmed: 23719559
Gastroenterology. 2017 Oct;153(4):1026-1039
pubmed: 28624575
Microb Pathog. 2018 Mar;116:13-21
pubmed: 29306011
J Microbiol Methods. 2013 Mar;92(3):387-97
pubmed: 23266580
Nat Rev Gastroenterol Hepatol. 2015 Feb;12(2):77-87
pubmed: 25385227
Sci Rep. 2015 Oct 12;5:14600
pubmed: 26455903
Genomics. 2011 Aug;98(2):152-3
pubmed: 21651976
J Clin Gastroenterol. 2014 Jul;48(6):513-23
pubmed: 24275714
Nature. 2009 Jan 22;457(7228):480-4
pubmed: 19043404
Nature. 2012 Oct 4;490(7418):55-60
pubmed: 23023125
Am J Gastroenterol. 2009 Jul;104(7):1745-53
pubmed: 19471251
Endocrinology. 2012 Aug;153(8):3613-9
pubmed: 22673227
Scand J Gastroenterol. 2008;43(7):831-41
pubmed: 18584522
Physiol Rev. 2017 Jan;97(1):411-463
pubmed: 28003328
Cell Metab. 2015 Aug 4;22(2):228-38
pubmed: 26244932
Genes (Basel). 2017 Dec 29;9(1):
pubmed: 29286343
Gut. 2011 May;60(5):631-7
pubmed: 21209126
Eur J Endocrinol. 2018 Jan;178(1):43-56
pubmed: 28916564
Nature. 2013 Aug 29;500(7464):541-6
pubmed: 23985870
Front Microbiol. 2016 Aug 03;7:1227
pubmed: 27536299
Proc Natl Acad Sci U S A. 2009 Oct 6;106(40):17187-92
pubmed: 19805153
Med Hypotheses. 2017 Sep;107:81-89
pubmed: 28915970
N Engl J Med. 2017 Sep 21;377(12):1143-1155
pubmed: 28930514